The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antitumor activity of  nab-paclitaxel and gemcitabine in resectable pancreatic cancer.
Rafael Alvarez-Gallego
No relevant relationships to disclose
Antonio Cubillo
No relevant relationships to disclose
Jesus Rodriguez-Pascual
No relevant relationships to disclose
Yolanda Quijano
No relevant relationships to disclose
Emilio De Vicente
No relevant relationships to disclose
Lina García
No relevant relationships to disclose
Fernando López-Ríos
Research Funding - Celgene
Carlos Plaza
No relevant relationships to disclose
Elena García-García
No relevant relationships to disclose
María Pia Morelli
No relevant relationships to disclose
Manuel Hidalgo
Honoraria - Celgene